CN105073739B - 用于制备吲唑衍生物的中间体及其制备方法 - Google Patents

用于制备吲唑衍生物的中间体及其制备方法 Download PDF

Info

Publication number
CN105073739B
CN105073739B CN201480009452.4A CN201480009452A CN105073739B CN 105073739 B CN105073739 B CN 105073739B CN 201480009452 A CN201480009452 A CN 201480009452A CN 105073739 B CN105073739 B CN 105073739B
Authority
CN
China
Prior art keywords
compound
formula
alkali metal
catalyst
value
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480009452.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN105073739A (zh
Inventor
T.C.伊里
B.P.哈彻
D.朱恩格斯特
S.R.斯潘塞
P.J.施滕格尔
D.J.沃森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN105073739A publication Critical patent/CN105073739A/zh
Application granted granted Critical
Publication of CN105073739B publication Critical patent/CN105073739B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480009452.4A 2013-02-27 2014-02-27 用于制备吲唑衍生物的中间体及其制备方法 Active CN105073739B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361770031P 2013-02-27 2013-02-27
US61/770,031 2013-02-27
PCT/US2014/019039 WO2014134313A1 (en) 2013-02-27 2014-02-27 Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
CN105073739A CN105073739A (zh) 2015-11-18
CN105073739B true CN105073739B (zh) 2017-10-24

Family

ID=50288305

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480009452.4A Active CN105073739B (zh) 2013-02-27 2014-02-27 用于制备吲唑衍生物的中间体及其制备方法

Country Status (5)

Country Link
US (1) US9790206B2 (enExample)
EP (1) EP2961744B1 (enExample)
JP (1) JP6433922B2 (enExample)
CN (1) CN105073739B (enExample)
WO (1) WO2014134313A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089646A1 (en) * 2006-01-31 2007-08-09 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
US20100022529A1 (en) * 2008-07-24 2010-01-28 Tiechao Li Amidophenoxyindazoles useful as inhibitors of c-met

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL214032B1 (pl) 2003-03-03 2013-06-28 Array Biopharma Zwiazki bedace inhibitorami kinazy p38, kompozycja farmaceutyczna je zawierajaca oraz ich zastosowanie do wytwarzania leku do leczenia stanu, w którym posredniczy kinaza p38
CA2647949A1 (en) * 2006-03-29 2007-11-08 Array Biopharma Inc. P38 inhibitors and methods of use thereof
KR20120104512A (ko) * 2009-07-14 2012-09-21 알바니 몰레큘라 리써치, 인크. 5-ｈｔ3 수용체 조절체, 이의 제조 방법, 및 그의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089646A1 (en) * 2006-01-31 2007-08-09 Array Biopharma Inc. Kinase inhibitors and methods of use thereof
US20100022529A1 (en) * 2008-07-24 2010-01-28 Tiechao Li Amidophenoxyindazoles useful as inhibitors of c-met

Also Published As

Publication number Publication date
JP2016516670A (ja) 2016-06-09
JP6433922B2 (ja) 2018-12-05
EP2961744B1 (en) 2017-06-28
WO2014134313A1 (en) 2014-09-04
EP2961744A1 (en) 2016-01-06
CN105073739A (zh) 2015-11-18
US20160002210A1 (en) 2016-01-07
US9790206B2 (en) 2017-10-17

Similar Documents

Publication Publication Date Title
JP7398510B2 (ja) ７－（４，７－ジアザスピロ［２．５］オクタン－７－イル）－２－（２，８－ジメチルイミダゾ［１，２－ｂ］ピリダジン－６－イル）ピリド［１，２－ａ］ピリミジン－４－オン誘導体の製造方法
JP2022166011A (ja) ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法
CN104024262B (zh) 埃克替尼和盐酸埃克替尼的制备方法及其中间体
TWI631121B (zh) 製備細胞凋亡誘導劑的方法
JP2022505189A (ja) 新規な工程
CN109071491B (zh) 吲唑的合成
CN101553461A (zh) 4-取代的苯氧基苯基乙酸衍生物
CN102307845A (zh) 盐酸西那卡塞特的制备方法
CN105073739B (zh) 用于制备吲唑衍生物的中间体及其制备方法
CN113480485B (zh) 一种1,2,4-三芳基-1,2,4-三唑烷类化合物及其合成方法
CN111606889A (zh) 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法
KR20200093705A (ko) 신규한 결정성 아릴알킬아민 화합물 및 그의 제조 방법
CN115448848A (zh) 一种抗真菌化合物制备方法
CN114394884A (zh) 一种烯丙基苯酚类化合物的制备方法
CN105198829B (zh) 一种可比司他中间体的制备方法及其中间体和用途
CN104230723B (zh) 托瑞米芬的合成方法
CN103664577B (zh) 一种西那卡塞中间体的制备方法
CN106588787A (zh) 一种含芳甲酰基1,2,3‑三氮唑类配体及其制备方法和应用
EP3215489A1 (en) Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
CN104496995A (zh) 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法
CN111620821B (zh) 取代的吡唑类化合物及包含该化合物的组合物及其用途
CN114805170A (zh) 一种新型赛洛多辛手性中间体的制备方法
CN116063318A (zh) 一种瑞卢戈利及其中间体的制备方法
CN115286623B (zh) 普克鲁胺的合成方法和其中间体
CN100528863C (zh) 舍吲哚的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant